Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.

Autor: Choudhury NJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York., Marra A; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Sui JSY; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Flynn J; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Yang SR; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Falcon CJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Selenica P; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Schoenfeld AJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York., Rekhtman N; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Gomez D; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Berger MF; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Ladanyi M; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Arcila M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Rudin CM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York., Riely GJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York., Kris MG; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York., Heller G; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Reis-Filho JS; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Yu HA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York. Electronic address: yuh@mskcc.org.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2023 Apr; Vol. 18 (4), pp. 463-475. Date of Electronic Publication: 2022 Dec 06.

Altered expression of ACOX2 in non-small cell lung cancer.

Autor: Sui JSY; Thoracic Oncology Research Group, Laboratory Medicine and Molecular Pathology, Central Pathology Laboratory, St. James's Hospital, Dublin, D08RX0X, Ireland.; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA., Martin P; Thoracic Oncology Research Group, Laboratory Medicine and Molecular Pathology, Central Pathology Laboratory, St. James's Hospital, Dublin, D08RX0X, Ireland.; Midland Regional Hospital Tullamore, Tullamore, Ireland., Keogh A; Thoracic Oncology Research Group, Laboratory Medicine and Molecular Pathology, Central Pathology Laboratory, St. James's Hospital, Dublin, D08RX0X, Ireland., Murchan P; Department of Histopathology and Morbid Anatomy, Trinity College Dublin, Dublin, Ireland.; School of Mathematics, Statistics, and Applied Mathematics, National University of Ireland Galway, Galway, Ireland., Ryan L; Department of Histopathology, Labmed Directorate, St. James's Hospital, Dublin, Ireland., Nicholson S; Department of Histopathology, Labmed Directorate, St. James's Hospital, Dublin, Ireland., Cuffe S; HOPE Directorate, St James's Hospital, Dublin, Ireland., Broin PÓ; School of Mathematics, Statistics, and Applied Mathematics, National University of Ireland Galway, Galway, Ireland., Finn SP; Thoracic Oncology Research Group, Laboratory Medicine and Molecular Pathology, Central Pathology Laboratory, St. James's Hospital, Dublin, D08RX0X, Ireland.; Department of Histopathology and Morbid Anatomy, Trinity College Dublin, Dublin, Ireland.; Department of Histopathology, Labmed Directorate, St. James's Hospital, Dublin, Ireland.; Cancer Molecular Diagnostics, Labmed Directorate, St. James's Hospital, Dublin, Ireland., Fitzmaurice GJ; Surgery, Anaesthesia and Critical Care Directorate, St James's Hospital, Dublin, Ireland., Ryan R; Surgery, Anaesthesia and Critical Care Directorate, St James's Hospital, Dublin, Ireland., Young V; Surgery, Anaesthesia and Critical Care Directorate, St James's Hospital, Dublin, Ireland., Gray SG; Thoracic Oncology Research Group, Laboratory Medicine and Molecular Pathology, Central Pathology Laboratory, St. James's Hospital, Dublin, D08RX0X, Ireland. sgray@stjames.ie.; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland. sgray@stjames.ie.; School of Biological Sciences, Technological University Dublin, Dublin, Ireland. sgray@stjames.ie.

Publikováno v: BMC pulmonary medicine [BMC Pulm Med] 2022 Aug 23; Vol. 22 (1), pp. 321. Date of Electronic Publication: 2022 Aug 23.

Pre-clinical models of small cell lung cancer and the validation of therapeutic targets.

Autor: Sui JSY; Thoracic Oncology Research Group, Laboratory Medicine and Molecular Pathology, Central Pathology Laboratory, St. James's Hospital, Dublin, Ireland.; Department of Medical Oncology, Mater Misericordiae University Hospital, Dublin, Ireland., Martin P; Thoracic Oncology Research Group, Laboratory Medicine and Molecular Pathology, Central Pathology Laboratory, St. James's Hospital, Dublin, Ireland., Gray SG; Thoracic Oncology Research Group, Laboratory Medicine and Molecular Pathology, Central Pathology Laboratory, St. James's Hospital, Dublin, Ireland.; Labmed Directorate, St. James's Hospital, Dublin, Ireland.; School of Biological Sciences, Dublin Institute of Technology, Dublin, Ireland.

Publikováno v: Expert opinion on therapeutic targets [Expert Opin Ther Targets] 2020 Mar; Vol. 24 (3), pp. 187-204. Date of Electronic Publication: 2020 Feb 26.

Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer.

Autor: Yen-Ting Lin^1,2,3, Chao-Chi Ho³, Wei-Hsun Hsu⁴, Wei-Yu Liao³, Ching-Yao Yang³, Chong-Jen Yu^3,5, Tzu-Hsiu Tsai³, James Chih-Hsin Yang^6,7,8, Shang-Gin Wu^2,3, Chia-Lin Hsu³, Min-Shu Hsieh^9,10, Yen-Lin Huang¹⁰, Chia-Ling Wu¹¹, Jin-Yuan Shih^1,3 jyshih@ntu.edu.tw

Publikováno v: Cancer Medicine. Jan2024, Vol. 13 Issue 1, p1-14. 14p.

Identification and validation of oxidative stressrelated genes in primary open-angle glaucoma by weighted gene co-expression network analysis and machine learning.

Autor: Lu-Qian Yang, Yue Song, Feng Huang, Wei Wu, Hong-Pei Ji

Publikováno v: Medicine; 11/15/2024, Vol. 103 Issue 46, p1-10, 10p